C olorectal cancer (CRC) screening reduces the risk of CRC mortality but is currently not well used, with adherence only 50% in the eligible US population and rates that lag behind those for breast and cervical cancer. The primary care physician has the pivotal role of facilitating patient adherence to CRC screening by informed choice of the screening tests, follow-up of positive tests, and coordination of medical resources when diagnostic intervention is required. Consequently, the primary care setting is where significant improvements can be made in CRC screening adherence. This article provides a summary of the newer CRC screening technologies that can be used by primary care physicians in shared decision making with their patients. There are now multiple CRC screening tests that vary in their ability to detect the different stages in the adenoma to carcinoma sequence. recommend a menu of CRC screening options, including fecal occult blood tests (FOBT) (Hemoccult II, Hemoccult SENSA, fecal immunochemical tests ͓FIT͔), double contrast barium enema (DCBE), flexible sigmoidoscopy with or without annual FOBTs, and colonoscopy. In this report, we assess the options of fecal immunochemical tests, colonoscopy, CT-colonography (CTC or virtual colonoscopy), and fecal DNA tests. The tests are discussed with respect to the evidence in support of their use and within the context of how they could be managed and implemented in primary care practice. Primary care physicians will want to understand the tradeoffs among accuracy, costs, and patient preferences for the current and emerging CRC tests.
INTRODUCTION
CRC is the second leading cause of cancer death in the United States, and yet this mortality burden can be largely prevented with screening. Primary care practitioners are in a unique position to facilitate CRC screening but face at least 3 challenges because of dynamically evolving CRC screening technologies: facilitating informed patient choice among the various possible options for screening; enabling patient follow-through with the screening process; and ensuring coordination and communication between the patient and the various physicians and healthcare organizations involved in screening and diagnostic follow-up. There are now multiple CRC screening tests that vary in their ability to detect the different stages in the adenoma to carcinoma sequence. The original guaiac-based CRC test (Hemoccult II) was used to detect CRC at an early stage. Most of the newer tests have at least some capacity to detect the larger adenomas and thus reduce CRC incidence as well as mortality. In this article, we discuss 4 CRC screening tests representing different stages of intervention, degree of invasiveness, frequency of repeat testing, and level of acceptance by patients.
Guidelines of the Multi-Society (Gastroenterology) Task Force, [1] [2] [3] [4] the American Cancer Society, 4 -7 and the United States Preventive Services Task Force (USPSTF) 8 recommend a menu of CRC screening options. The new 2008 guidelines by the Multi-Society Task Force (MSTF) for individuals at average risk are shown in Table 1 . 4 These guidelines classify the screening tests as those tests that detect adenomatous polyps and CRC (structural examination tests) and those that primarily detect CRC (fecal tests). These guidelines make an important distinction between the sensitivity achieved in a single test at one point in time (test sensitivity) and the sensitivity of a test used serially over time in a program of repeat screening (programmatic sensitivity). FIT is based on 2 to 3 separate bowel movements with 2 samples per movement depending on the manufacturer. ¶ Barium enema was part of the original guidelines with repeat testing at 5 yr but its use as a primary screening tool has diminished because of its low sensitivity for detection of large adenomas. 67 For the combined strategy of Flex Sig and FOBT, the FOBT is done first and if negative then the flex sig is done.
The new guidelines require test sensitivity of 50% or higher for detection of CRC for that test to be included in the menu of recommended tests. Screening intervals and colonoscopic surveillance for those with adenomas or CRC detected have also been specified. Repeated screening for those with negative results and surveillance for those with adenomas detected are essential components to a program of CRC screening. In 2002 the USPSTF 8 stated that there was sufficient evidence to recommend CRC screening for average risk individuals beginning at age 50 but insufficient evidence to recommend 1 test over the other. Updated recommendations from the USPSTF are expected in 2008.
Fecal occult blood test (FOBT) is the only CRC screening approach demonstrated to be effective in randomized controlled trials. Depending on whether the tests were done biennially or annually, and whether they were rehydrated or not, FOBT was associated with a 15-33% reduction in CRC mortality, 9 -12 and a 17-20% reduction in CRC incidence. 13 The Hemoccult II test, which was used for these 3 randomized controlled trials, has high specificity (98%) but lower one-time test sensitivity (40%). However, when Hemoccult II is used in a program of annual screening, the overall sensitivity for CRC for the multiple period testing (program sensitivity) is higher. Hemoccult II test sensitivity for the larger adenomas (Ն1.0 cm) is markedly lower than for CRC. Consequently, the CRC mortality reduction observed in these 3 randomized controlled trials was mainly due to the detection of early curable cancer rather than prevention of CRC. The recent MSTF guidelines no longer recommend the Hemoccult II test for CRC screening, because of its lower per test sensitivity for CRC but do recommend the more sensitive Hemoccult SENSA guaiac-based test. 4 Quality control is required in developing the guaiac slide. 14 -16 In this article, we assess the options of fecal immunochemical tests, colonoscopy, CT-colonography (CTC) (virtual colonoscopy), and stool DNA tests as tools to increase the impact and participation in CRC screening. These tests are discussed within the context of how they could be managed and implemented within primary care practice. Fecal immunochemical tests (FIT) and colonoscopy have previously been placed in the recommended strategies. However, CTC and stool DNA are newly included in the MSTF guidelines with caveats as these tests continue to evolve. 4 In setting its initial guidelines in 1997 1 the MSTF noted that new tests could be considered for inclusion without evidence from a randomized controlled trial demonstrating a CRC mortality reduction if the newer test had comparable or better test performance (sensitivity and specificity) in detecting CRC or adenomas as currently recommended tests; was equally or more acceptable to patients; and had comparable or lower complication rates and costs.
A summary of sensitivity, specificity, and payer costs for the CRC screening tests is given in Table 2 .
FECAL IMMUNOCHEMICAL TESTS

Origin
Since the publication of the landmark studies for the guaiac-based fecal occult blood test (GT), newer tests for fecal occult blood have been approved for clinical use in the United States. CRC and some of the larger adenomas have a tendency to bleed sporadically. The guaiac tests use the peroxidase activity of heme or hemoglobin as an indicator of occult blood. The Hemoccult SENSA test was developed as a qualitative test to detect lower levels of peroxidase activity than Hemoccult II and has higher sensitivity but lower spec- *Sensitivity is provided per individual patient for stool-based tests and per lesion for endoscopy tests. We make the assumption that the FOBT tests cannot detect adenomas of size Ͻ1.0 cm and that detection of such adenomas would be due primarily to a false positive findings (denoted by italics for these size lesions 37 ; publication of these results is expected. Vanness, personal communication. **The lack of specificity with colonoscopy and sigmoidoscopy screening reflects the detection of non-adenomatous lesions. With colonoscopy these non-adenomatous lesions are removed and therefore induce polypectomy costs. With sigmoidoscopy the presence of non-adenomatous lesions induces biopsy costs (in case of sigmoidoscopy with biopsy) or results in referral for diagnostic colonoscopy (in case of sigmoidoscopy without biopsy).
† † With and without polypectomy; polypectomy has additional pathology review charges. ‡ ‡ Test characteristics for sigmoidoscopy only apply to the distal colon and rectum. ificity than the Hemoccult II test given that peroxidase activity is found in plants and nonhuman blood such as in red meat. The FIT is based on detection of human globin. These tests were developed as a quantitative test for occult blood in the stool that did not require the 3-day dietary restrictions of the Hemoccult II test. There is evidence that FITs are more sensitive than standard GTs, such as Hemoccult II. 17 There is also mounting evidence that FITs may have better sensitivity than Hemoccult SENSA, 18, 19 with comparable specificity.
Evidence-Based Results
The standard hemoglobin concentration in most studies of FITs has been 100 ng of hemoglobin per milliliter of blood. At this concentration, results have varied somewhat between settings, by the number of samples, and the gold standard used to determine true prevalence of cancer and advanced adenomas. All studies have evaluated one-time testing of the FIT test (test sensitivity). In a preventive health HMO population, Allison et al 17 Three studies have directly compared the sensitive GT (Hemoccult SENSA) to a FIT, in a population large enough to obtain relatively precise point estimates of sensitivity and specificity ( Table 3 ). [17] [18] [19] In 1 study in which a standard GT (Hemoccult II) was used, both the sensitive GT and the FIT showed improved sensitivity (37.1% vs. 68.8% vs. 79.4%), but with a much lower specificity for the sensitive GT. 17 At the current time, due to heterogeneity in the evidence, it is difficult to say that 1 FIT is clearly superior. Sensitivity and specificity point estimates have varied across studies due to differences in populations and the criterion standard used to determine true incidence of cancer.
Practice Implications
FOBT, although not as sensitive for colorectal adenomas as colonoscopy, CT colonography or flexible sigmoidoscopy, offers the advantage of being noninvasive, and convenient for individuals. Tests can be sent through the mail directly to individuals; samples are collected in the privacy of their homes, and can be returned by mail to a central processing laboratory. Patient acceptance is apt to be higher with FITs, because of the need for only 1 or 2 samples rather than 3 for the guaiac-based tests. No dietary or medication restrictions are needed, because these tests are specific for human hemoglobin, and are specific for colonic bleeding. Selected FITs offer the option of automated test reading, which may result in improved precision and reliability of the interpretation, and the possibility of reporting a quantitative result, with resultant trade-offs in sensitivity and specificity. 21 Given that the guaiac-based FOBT has been found to be effective in randomized controlled trials and is considered a proven method for CRC screening by the USPSTF, the newer FOBTs such as the FIT with increased sensitivity and roughly the same specificity as the original guaiac-based FOBT, even at higher cost, are an increasingly used option for CRC screening.
Some patients and providers will opt for invasive endoscopic or CT colonographic screening, but there will be a limit on the population screening rate based on patient acceptance and available capacity. 22 To achieve the goal of population screening, a noninvasive, efficient, and scalable option will be needed. In these regards, the FIT is a promising alternative to conventional GT (Hemoccult II) and a promising complement to colonoscopy. However, patients must be aware that a positive FOBT must be followed up with colonoscopy for evaluation.
COLONOSCOPY Origins
Colonoscopy was first introduced in the 1970s as a method to visualize the entire colon. In 1973, Wolf and Shinya 23 demonstrated the feasibility of colonoscopic polypectomy that initiated using colonoscopy as both a diagnostic and therapeutic tool. The ability of colonoscopy to visualize (ie, optically) and remove polyps greatly enhanced the feasibility of FOBT and sigmoidoscopy screening programs, where colonoscopy could be used to evaluate positive FOBT or sigmoidoscopy findings.
Technical Evolution
Fiberoptic colonoscopes were replaced by digital video-endoscopy that enhanced visual detection of polyps and provided a record of the reach to the cecum, postpolypectomy site, and cleanliness of the bowel. Technical improvements have facilitated polyp removal and maneuverability within the colon and rectum. 
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Evidence-Based Results
The National Polyp Study (NPS) was designed to assess how frequently a patient with an initial adenoma removed should be reevaluated, given that the adenoma was the precursor lesion for CRC. 24 The NPS required all participants to have a high quality colonoscopy that reached the cecum, with good bowel preparation, and all polyps removed. Thirteen percent of the adenoma patients enrolled had a repeat baseline colonoscopy to ensure a high-quality examination with removal of all polyps. In an analysis using historical controls, NPS found that adenoma polypectomy was associated with a reduction in CRC incidence of 76% compared with the general population and 90% compared with a polyp bearing population without polypectomy over an average 6-year period after initial polypectomy. 25 Although the NPS was not a screening population and did not have a concurrent control group for the adenoma patients, the results of high adherence and highly significant reduction in CRC with polypectomy were considered promising evidence for the use of colonoscopy as a primary screening tool. Further indirect evidence for the usefulness of colonoscopy came from the randomized controlled trials of FOBT, 9 -11 each of which had used colonoscopy to evaluate positive FOBT results. Colonoscopy provided the opportunity to intervene early in the adenoma-carcinoma sequence and to prevent CRC and its sequelae of surgical and chemotherapy treatment by removing adenomas, the precursor lesion.
The yield of clinically important lesions from colonoscopic screening has now been evaluated in studies in Veterans Administration patients, 26 military women, 27 Eli Lilly employees and retirees, 28 and Poland. 29 The Veterans Affairs (VA) study found a high yield of adenomas (38%) and advanced adenomas (18%) in its VA cohort, which was partially enriched by those with positive family history. 26 However, the other colonoscopy studies have had a lower yield of neoplastic findings. [27] [28] [29] Colonoscopic screening is invasive, requires a rigorous bowel cleansing, and sedation (in the United States) and is associated with risks of perforation and bleeding, especially from the polypectomy. 30 Risks as well as benefits need to be considered in using colonoscopy as the primary screening test. Given that it is generally conducted with sedation, a second person is needed to provide transportation after the procedure.
Practice Implications
Colonoscopy can be used as the primary screening tool or as the diagnostic and therapeutic tool after a positive FOBT, flexible sigmoidoscopy, or CTC test. In the 2-step procedure, colonoscopy is used to identify a higher risk population where the benefit of colonoscopic polypectomy would be greater than the possible harm associated with perforation or bleeding. Levin et al 31 and Imperiale et al 32 have suggested mixed modality screening of flexible sigmoidoscopy or FOBT at earlier ages and colonoscopy screening for older ages to identify the higher-risk persons from within the average risk population.
Colonoscopy as a screening and therapeutic tool continues to improve technologically. However, of particular importance is the emphasis on continuous quality improve-ment in performance as stated in the Multi Society Guidelines. 33, 34 The gastroenterology societies are working to provide tools for self-evaluation of endoscopic performance as a means to ensure high-quality colonoscopies. 35 
CT COLONOGRAPHY
Origins
The key conceptual basis for CTC-also called "Virtual Colonoscopy" or VC-arose over a decade ago when it was recognized that thin-slice contiguous abdominal CT images could be reconstructed in software to simulate visualization of the lumen of the colon and create a "fly-through" display presenting polyps as prominent irregularities. It took a dozen years for this approach, combined with other improvements, to reach maturity.
Technical Evolution
Between 2000 and 2002, commercial multirow detector CT scanners advanced from 4-row detector devices to 64-row assemblies, enabling high-speed imaging of the total abdomen within a single breath-hold, thus nearly eliminating motion artifacts that had bedeviled earlier efforts. Hardware and software innovations also made possible multiplanar displays and visually-compelling 3D dynamic simulations. A last critical contribution was the development of bowel prep procedures that optimized polyp visualization.
Evidence-Based Results
The public health implication of CTC would be its utilization as an efficient screening filter for optical colonoscopy. Ideally, CTC might efficiently deflect from optical colonoscopy consideration many in the average risk population who do not harbor significant premalignant adenomas. This would lower the known colonoscopy risks of sedation and perforation.
Given the field's rapid technical and practice evolution determining how ready this approach is for public health deployment requires careful consideration of recent evidence. Highest quality evidence is best provided by prospectively designed large cohort multi-institutional trials using advanced (Ͼ16 detector array) CT scanners with visualization software and oral contrast colonic preps. In well designed screening trials of asymptomatic subjects, the CTC polyp findings on each individual should be validated for each subject by proceeding sequentially to colonoscopy to confirm the presence or absence of polyps. CTC must convincingly demonstrate that it has both high sensitivity and high specificity to minimize the number of subjects proceeding unnecessarily to optical colonoscopy. Two such reports exist. One 3-site, 1233 subject trial was published in 2003 36 reporting CTC sensitivity of 94% for polyps Ͼ1 cm in size (specificity was 96%). The other is a national 15-institution prospective trial (ACRIN 6664: National CT Colonography Trial) that accrued 2531 subjects reporting a 90% sensitivity per patient for Ն1 cm polyps and an 86% specificity. 37 For polyps as small as 7 mm, the latter trial reported sensitivity and specificity of 84% and 87%, respectively. 
Practice Implications
Additional questions raised by the advent of this technology are now being addressed in the literature. These include:
• Current MSTF guidelines state that all patients with one or more polyps Ն6 mm detected by CTC should be referred for colonoscopy. 4 Although there is clear consensus that patients with larger polyps (Ն10 mm) or with 3 or more polyps with the largest 6 -9 mm in size should be referred to colonoscopy, the management for patients with 1 or 2 polyps of size 6 -9 mm is not well established. Under continued discussion is whether polyps Ͻ6 mm in size require accurate detection and removal or can they be adequately addressed by continued observation by CTC and at what intervals. 4 Some have asked this same question about polyps 6 -9 mm. • Is CTC radiation dosage significant? Although CT scanning conveys a small degree of radiation risk, the lifetime cancer risk for individuals older than 50 is arguably minimal for CTC 38 . The question remains as to whether overall CTC procedures significantly contribute to patients' exposure to ionizing radiation. • What is the professional capacity for conducting CTC screening? CTC is operator dependent for high quality examinations. Responsible incorporation of CTC into practice should logically encourage a single bowel prep strategy with the assumption that approximately 10% of individuals would be polyp positive and should proceed to a same-day optical colonoscopy examination. This would require coordination of resources. Since CTC necessitates advanced technology and a properly skilled observer, it will benefit from (1) professional standards assuring appropriate CT scanner technology, (2) integrated visualization software, (3) verified qualifications on the part of the image practitioners, (4) CT image archiving and auditability, (5) structured clinical reporting, (6) transparent recording of the clinical consequences of extracolonic findings, and (7) meticulous record-keeping process that justifies confidence in any practice sensitivity and specificity claims.
The new 2008 MSTF guidelines 4 include CTC as a CRC screening test option, even though they state that additional research is needed to establish practice parameters for surveillance and repeat screening. However, insurance coverage for CTC is currently limited.
FECAL DNA TEST
Origin
Fecal DNA testing represents a new noninvasive approach to CRC screening. The approach has been made possible by elucidation, over the last 2 decades, of the molecular "pathway" or changes that occur as colon mucosa progresses from normal tissue to adenoma and to CRC. 40 -44 These changes provide "targets" that an assay can be designed to detect. Simultaneous technological advances have allowed human DNA to be separated and purified from stool and to be amplified and analyzed. 43, 45, 46 An approach that measures DNA in stool has at least a theoretical advantage over an approach that measures bleeding, like FOBT. The discriminatory ability of FOBT testing depends on 2 features of biology: first, the degree to which neoplasms bleed; second, how much does that rate of bleeding exceed normal blood loss. To the extent that neoplasms do not bleed (or do not bleed more than "normal"), they cannot be "detected" by any FOBT, no matter how "sensitive" an assay may be made. Similarly, for fecal DNA testing the rate-limiting step is whether neoplasms have DNA changes that are shed into stool and can be measured, and whether those changes "exceed" those of a normal person. The possible theoretical advantage of stool DNA testing is that, because cancer is a disease of multiple mutations, a stool DNA assay might be made "sensitive enough" if the right markers can be discovered and measured. These considerations are theoretical; how they actually play out quantitatively, for either approach, must be determined by empirical evidence from clinical research studies.
Technical Evolution
Although preliminary results have been reported for several methods of assessing alterations in stool DNA, [47] [48] [49] [50] [51] [52] [53] only one major prospective-blinded study has been done in a screening setting. 54 The first-generation DNA assay that was tested included multiple mutations of the APC, K-ras, and P53 genes that are in the "pathway" described by Vogelstein et al, 40 -44 along with BAT-26, a marker of mismatch-repairpathway tumors.
Evidenced-Based Results
Based on promising preliminary results, 47,55 a multicenter prospective study was planned so that patients received colonoscopy after stools had been collected. The assay consisted of 22 specific gene mutations and a "DNA integrity assay" (DIA) 54 that measures the size of DNA fragments that are shed in stool; in those with CRC, the DNA in stool may be longer than in those who are normal. The panel consisting of these multiple markers was considered positive if any marker was positive. The first-generation panel had a 52% sensitivity for CRC and specificity of 94%. 54 In contrast, guaiac-based FOBT (Hemoccult II) completed at home with office-based testing had a sensitivity of 13% and specificity of 95%. Although these results represented an advance over FOBT, they were not as strong as in preliminary studies and were considered not sufficient to support a practical commercially available test. 56 A second-generation assay used improved DNA stabilization techniques (particularly important for the DNA integrity assay) and included a new promoter methylation marker. While methylation occurs in CRC, [57] [58] [59] its role in carcinogenesis is not known. A study of a "second-genera- tion" assay compared stools from known CRC subjects to healthy subjects and showed that using just 2 markers resulted in an "optimal combination of vimentin methylation plus DIA. . . ͓with͔ 87.5% sensitivity and 82% specificity". 60 Further clinical confirmation of these second-generation results is necessary in a general population asymptomatic screening population.
Practice Implications
In the future, the potential usefulness of stool DNA testing may be affected by several developments. First, sensitivity and specificity might be further improved by combining (or replacing) current markers with other markers. However, the current commercial cost (January 2008) is $800, although group practices or insurers may negotiate substantial discounts, and represents a significant financial barrier for some patients.
No version of the currently available stool DNA test has received US Food and Drug Administration (FDA) approval.
FDA has determined that the only commercially available DNA-stool test, PreGen-Plus TM , requires premarket review. Although CMS was asked to provide a national coverage determination for the stool DNA test, they will not consider expanding Medicare's CRC screening coverage to include the stool DNA test until a commercially available stool DNA test has been cleared or approved by the FDA. CMS also requested a decision analysis of the stool-DNA test based on microsimulation modeling of the currently available studies and with an estimated cost of $350 per test. The modeling group concluded that only if significant improvements in test characteristics or relative adherence with DNA stool testing compared with available options can be demonstrated, will stool DNA testing at the current costs of $350 be cost effective. 61 The interval for retesting and the significance of false positive stool DNA tests are not currently known.
The MSTF now includes the stool DNA test in its recommended screening strategies but notes that stool DNA is an evolving test and cautions that new iterations of these tests must be carefully evaluated for acceptable test performance. This guideline group also noted that there is insufficient evidence to establish a repeat screening interval for those with a negative stool DNA test.
DISCUSSION
Two main approaches to CRC screening are currently prevalent in the United States. One is to use colonoscopy as the primary screening tool. The other is to use a less invasive initial screening test to triage those at higher risk for CRC or adenomas to colonoscopy. Candidates for this initial test include the stool based tests (guaiac-based Hemoccult SENSA, the new fecal immunochemical tests, or the fecal DNA test) or structural examinations (flexible sigmoidoscopy or CTC colonography).
Physician recommendation for CRC screening has an important impact on increasing adherence but also requires time and commitment from the primary care practitioners to explain the benefits and risks associated with CRC screening. 62 With a decentralized system of healthcare delivery in the United States, primary care providers are central to implementing CRC screening guidelines. This is a challenging role because unlike screening for other cancers, there are multiple tests options that require explanation and discussion as to which test strategy to select for each patient. Schwartz 63 suggests that too much choice can lead to inaction or even bad decisions and recommends far fewer choices in medical decisions in which the patient is to have a major role. Also, CRC screening requires far more effort on the patient's part than for other preventive screening services. These challenges may contribute to CRC screening rates that are markedly lower than for breast or cervical cancer. 64 The challenge of implementing CRC screening in the average risk population in primary care practice could be managed with the use of the evidence based New Model of Primary Care Delivery 65 that uses: (1) a team approach with responsibility for screening tasks shared among members of the practice to deliver the message for CRC screening and the logistics for screening; (2) information systems for identifying eligible patients and reminding them when screening is due; (3) involving patients in shared decision making about their preferences for screening; (4) information systems to target patients at increased risk because of family history or social disadvantage; (5) reimbursement for services outside the traditional provider-patient encounter, such as telephone or e-mail contacts to enhance screening adherence; and (6) provider training opportunities in communication, cultural competence, and use of information programs to facilitate CRC screening. The goal of the primary care physician is to educate and facilitate CRC screening by recommending CRC screening; discussing available screening options; performing the CRC screening test or referring to an appropriate specialist, and ensuring that all positive tests are evaluated with colonoscopy.
The currently available CRC screening tests will continue to improve with technology advances. Primary care physicians will need to be vigilant about keeping current with technology improvements and updated guidelines in this rapidly evolving field.
